Clinical Trial Search

Primary: Adherence to Regional Guidelines for the Immunization of Adults With Type 1 Diabetes Mellitus (T1DM — 165; 54; 51; 30 Participants

Primary: Serum Vitamin C Level at Baseline — 13372; 16079; 13111 ng/mL

Primary: Rate of Moderate and Severe AECOPD (Any Cause)-Analysis (87% Confidence Interval [CI]), Post-dose 2 and Lasting for 1 Year — 1.22; 1.17 exacerbations per person-year…

Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — -53.97; -41.01; -24.26; -17.24 percent change

Primary: Arterial Fraction — 79.8; 72.2; 73.6 percentage of arterial fraction — p=0.211

Primary: Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline — 0.934; 0.783; 0.709; 0.660…

Primary: Items to Define Conformity to Cabazitaxel Conditions of Use — 11 items

Primary: Percentage of Patients Who Did Not Experience an Inappropriate Shock From Their EMBLEM S-ICD — 95.9 Percentage of participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Vaccine Regimen — 16; 18; 16; 7 Participants

Primary: Change in Stop Signal Reaction Time — -8.62 ms — p=.003

Primary: SPI24 — 85.0; 106.8 units on a scale

Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Including by Severity, During Single-dose Phase — 1; 2; 0; 1 Participants

Primary: Number of Angina Episodes Per Week at 6 and 12 Months — 6.8; 8.3; 10.9; 6.3 angina episodes/week — p=0.020

Primary: PCA (Patient Controlled Analgesia) Usage

Primary: Change From Baseline in 4-hour Mixed Meal Tolerance Test (MMTT)-Stimulated C-peptide Area Under the Curve (AUC) at Week 52 — -0.2863; -0.3895; -0.2670 pmol*hr/mL